INBX vs. FUSN, BEAM, ADMA, DNA, NMRA, RXRX, TARS, SANA, FDMT, and APGE
Should you be buying Inhibrx stock or one of its competitors? The main competitors of Inhibrx include Fusion Pharmaceuticals (FUSN), Beam Therapeutics (BEAM), ADMA Biologics (ADMA), Ginkgo Bioworks (DNA), Neumora Therapeutics (NMRA), Recursion Pharmaceuticals (RXRX), Tarsus Pharmaceuticals (TARS), Sana Biotechnology (SANA), 4D Molecular Therapeutics (FDMT), and Apogee Therapeutics (APGE). These companies are all part of the "biological products, except diagnostic" industry.
Inhibrx (NASDAQ:INBX) and Fusion Pharmaceuticals (NASDAQ:FUSN) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, profitability, dividends, valuation, earnings, community ranking, risk and analyst recommendations.
82.5% of Inhibrx shares are held by institutional investors. Comparatively, 72.9% of Fusion Pharmaceuticals shares are held by institutional investors. 22.2% of Inhibrx shares are held by company insiders. Comparatively, 7.8% of Fusion Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
In the previous week, Inhibrx had 1 more articles in the media than Fusion Pharmaceuticals. MarketBeat recorded 1 mentions for Inhibrx and 0 mentions for Fusion Pharmaceuticals. Fusion Pharmaceuticals' average media sentiment score of 1.00 beat Inhibrx's score of 0.77 indicating that Fusion Pharmaceuticals is being referred to more favorably in the news media.
Fusion Pharmaceuticals received 10 more outperform votes than Inhibrx when rated by MarketBeat users. Likewise, 64.06% of users gave Fusion Pharmaceuticals an outperform vote while only 60.78% of users gave Inhibrx an outperform vote.
Inhibrx presently has a consensus target price of $27.00, suggesting a potential downside of 22.19%. Fusion Pharmaceuticals has a consensus target price of $20.25, suggesting a potential downside of 5.86%. Given Fusion Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Fusion Pharmaceuticals is more favorable than Inhibrx.
Inhibrx has a beta of 2.87, meaning that its share price is 187% more volatile than the S&P 500. Comparatively, Fusion Pharmaceuticals has a beta of -0.69, meaning that its share price is 169% less volatile than the S&P 500.
Fusion Pharmaceuticals has higher revenue and earnings than Inhibrx. Fusion Pharmaceuticals is trading at a lower price-to-earnings ratio than Inhibrx, indicating that it is currently the more affordable of the two stocks.
Fusion Pharmaceuticals has a net margin of -4,136.55% compared to Inhibrx's net margin of -13,408.95%. Fusion Pharmaceuticals' return on equity of -48.74% beat Inhibrx's return on equity.
Summary
Fusion Pharmaceuticals beats Inhibrx on 12 of the 18 factors compared between the two stocks.
Get Inhibrx News Delivered to You Automatically
Sign up to receive the latest news and ratings for INBX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding INBX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
